Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Upadacitinib Receives Breakthrough Designation, Abatacept Use Expands in Australia & More

  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. AbbVie. News release: AbbVie’s upadacitinib granted breakthrough therapy designation from the U.S. Food and Drug Administration for atopic dermatitis. 2018 Jan 8.
  2. Staff. Brief—third Australian indication approved for Orencia. ThePharmaLetter. 2018 Jan 22.
  3. Braeburn Pharmaceuticals. News release: Braeburn receives complete response letter for CAM2038 injectable buprenorphine depot. 2018 Jan 21.

Related Articles

    Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

    As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis fac­tor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medi­cine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…